FDA Sarclisa Approval Marks Sanofi's Reentry Into Oncology
Executive Summary
The anti-CD38 antibody will face an entrenched rival, J&J's Darzalex, for multiple myeloma.
You may also be interested in...
J.P. Morgan Day 2: Pharma Offers (Some) Views On Drug Pricing Reform
Daily round-up from the virtual J.P. Morgan Healthcare Conference: Novartis explains its PD-1 deal; Biogen partners with Apple; Sanofi and Merck discuss business development priorities; and why AbbVie is confident it can grow without relying on deals.
J.P. Morgan Day 2: Pharma Offers (Some) Views On Drug Pricing Reform
Daily round-up from the virtual J.P. Morgan Healthcare Conference: Novartis explains its PD-1 deal; Biogen partners with Apple; Sanofi and Merck discuss business development priorities; and why AbbVie is confident it can grow without relying on deals.
Sanofi’s Berger On Creating A Sleek R&D Engine Fit For Purpose In The 2020s
A change in direction for the French firm means a new approach to R&D. Sanofi’s global head of development and chief medical officer Dietmar Berger talked to In Vivo about what was needed to get the company’s R&D machine back on track.
Need a specific report? 1000+ reports available
Buy Reports